Anti-depressants in bipolar disorder: Quo vadimus?
Correspondence Sir, The use of anti-depressants in bipolar depression remains a controversial and emotive issue among mental health clinicians and practitioners. Despite the lack of a strong evidence base for treatment benefi ts with antidepressants for bipolar depression, [1] the reality is that most of us continue to recommend these agents for our patients. There are a number of issues that seem to cloud our judgment in this matter. On the one hand, there is evidence about a subset of individuals with bipolar disorder who may derive definite benefit from being put on anti-depressants when they are experiencing symptoms of depression, and on the other hand there are enduring concerns about their 'mood-destabilizing properties' -short-term switching from depression to hypomania or mania, and paucity of evidence of their long-term efficacy in treating bipolar depression. [2] Obviously, there is a need to take a balanced stance that is true to evidence and also takes into account the clinical complexities of presentation. In this regard, I wish to interpret and highlight the recent International Society for Bipolar Disorders (ISBD) task force recommendations on the use of anti-depressants in bipolar disorder, [3] which has relevance to clinical teaching and practice.
The experts' consensus appears to be clearly in favor of considering anti-depressants for bipolar depression in three situations: 1. When there is a positive history of a previous response to these agents 2. If there is a history of relapsing when taken off antidepressants 3. When there are less than two manic symptoms concurrent with depression, with minimal/no psychomotor agitation or rapid cycling.
Furthermore, as antidepressant-induced mood elevations are more common and more severe in Bipolar I than Bipolar II disorders, the recommendations are that monotherapy with anti-depressants should be strictly avoided in the former, and in the latter, when the depressive presentation is contaminated with two or more manic symptoms. Clinicians are discouraged from using anti-depressants in the presence of mixed features during manic or depressive presentations or in predominant mixed state presentations. Other factors that should deter one from initiating these agents include a history of rapid cycling or high mood instability (which may be interpreted as a high number of episodes) or a history of previous mania, hypomania or mixed episodes. Careful monitoring for signs of hypomania/mania or psychomotor agitation is advised in all cases receiving adjunctive anti-depressant therapy. Serotonin norepinephrine reuptake inhibitors (SNRI) or tricyclic anti-depressants (TCA) carry an increased risk of mood switch, and hence, are to be less preferred to Selective serotonin reuptake inhibitors (SSRI) in bipolar disorder.
To conclude, anti-depressants need not be treated as 'untouchables' in bipolar depression, provided a careful risk-benefi t assessment is carried out on a case by case basis and the above clinical caveats are kept in mind. There are huge unmet needs in the care of bipolar depression. This includes a lack of rigorous, long-term prophylactic efficacy trials. Only three agents -Olanzapine-Fluoxetine, Quetiapine, and Lurasidone are currently approved for treatment of this condition, which is disproportionate to its magnitude and impact. [4] Considering that bipolar patients spend most of their time in depression than mania or hypomania, [5] more research needs to be carried out in order to come up with effective agents that can limit the impact of depression in bipolar individuals.
